(6) Legislative and regulatory instruments are in place in most developed countries to prevent importation, in certain circumstances, of pharmaceutical products, but these instruments risk becoming insufficient where substantial volumes of heavily discounted pharmaceuticals are sold to the poorest developing country markets and the economic interest in trade diversion into high priced markets therefore may increase significantly.
(6) Enamikus arenenud riikides kehtivad õigusnormid, mis teatavates tingimustes takistavad farmaatsiatoodete importi, kuid need normid võivad osutuda ebapiisavaks, kui arengumaade turgudel müüakse märkimisväärsetes kogustes oluliselt vähendatud hinnaga ravimeid ning kui oluliselt suureneb majanduslik huvi nende kaubanduslikuks levitamiseks kõrgemate hindadega turgudel.